Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 15/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.39 |
| ▸ | ITGAL | P20701 | 15/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191123 | 0.80 | AR (0.41) | ICAM1GRM5TRPA1HPGD | |
| SCHEMBL191204 | 0.79 | HPGD (0.44) | GRM5TRPA1LMNAHPGD | |
| SCHEMBL14562023 | 0.74 | ITGB2 (0.67) | ITGB2ICAM1ITGAL | |
| SCHEMBL190818 | 0.74 | SIRT2 (0.44) | GRM5TRPA1LMNA | |
| SCHEMBL14113377 | 0.74 | SLC6A4 (0.50) | LMNA | |
| SCHEMBL191141 | 0.73 | TRPA1 (0.47) | GRM5TRPA1LMNAHPGD | |
| SCHEMBL191746 | 0.73 | ALDH1A1 (0.40) | ITGALGRM5TRPA1HPGD | |
| SCHEMBL192450 | 0.73 | AR (0.39) | ITGB2ICAM1ITGALGRM5TRPA1 | |
| SCHEMBL2888693 | 0.73 | GABRA1 (0.41) | LMNAHPGD | |
| SCHEMBL4808650 | 0.72 | GABRA1 (0.48) | ITGB2ICAM1ITGALLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| CN-101437512-A | Glucokinase activators | ARRAY BIOPHARMA INC (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | ITGB2 4540/4885ICAM1 4252/4885ITGAL 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.